Dr. Reddy’s Laboratories has announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the US Food and Drug Administration (USFDA).
The Renvela brand and generic had US sales of approximately $101 million MAT for the most recent twelve months period ending in October 2018, according to IMS Health.
Dr. Reddy’s Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90. Renvela is a trademark of Sanofi.